期刊文献+

莱博雷生片中莱博雷生的含量测定

Determination of lemborexant content in lemborexant tablets
下载PDF
导出
摘要 目的建立测定莱博雷生片含量的高效液相色谱法,为建立其质量标准提供依据。方法采用Alltima C_(18)色谱柱(150 mm×4.6 mm,5μm),以0.1%磷酸水溶液-乙腈(40∶60)为流动相;流速1.0 mL·min^(-1);检测波长282 nm,柱温30℃。结果莱博雷生在24.90~398.4μg·mL^(-1)与峰面积成线性关系,相关系数(r)为0.9999;重复性、精密度及稳定性良好,RSD分别为0.40%、0.20%及0.40%;平均加样回收率在99.34%~100.8%,RSD在0.70%~1.3%,3份样品中莱博雷生含量分别为标示量的93.48%、93.67%和93.46%。结论该方法准确、快速、简便,可用于莱博雷生片的含量测定。 Objective To determine lemborexant content in lemborexant tablets by high performance liquid chromatography(HPLC)and help establish its quality standard.Methods An Alltima C_(18) column(150 mm×4.6 mm,5μm)was used for the separation,with 0.1%phosphoric acid solutionacetonitrile(40∶60)as the mobile phase at the flow rate of 1.0 mL·min^(-1).The detection wavelength was 282 nm and the column temperature was 30℃.Results There was a good linearity between lemborexant and the peak area at 24.90~398.4μg·mL^(-1),with the correction coefficient(r)of 0.9999.Relative standard deviations(RSD)of repeatability,precision and stability were 0.40%,0.20%and 0.40%,respectively.The average spiked recovery was between 99.34%~100.8%with RSD of 0.70%~1.3%.The content of 3 emborexant samples was 93.48%,93.67%and 93.46%,respectively.Conclusion The method is rapid,simple,and accurate,which can be used for the content determination in lemborexant tablets.
作者 郭思瑞 徐文峰 徐硕 张闪闪 金鹏飞 GUO Si-rui;XU Wen-feng;XU Shuo;ZHANG Shan-shan;JIN Peng-fei(Department of Pharmaceutical Science,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Science,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730)
出处 《中南药学》 CAS 2023年第3期763-766,共4页 Central South Pharmacy
关键词 莱博雷生 失眠症 高效液相色谱 含量测定 lemborexant insomnia HPLC determination
  • 相关文献

参考文献3

二级参考文献12

  • 1Howland RH. Suvorexant: a novel therapy for the treatment of in- somnia[ J]. J Psychosoc Nurs Ment Health Serv , 2014, 52:23 -26. 被引量:1
  • 2Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia[ J]. Expert Rev Clin Pharmacol,2014, 7:711 - 730. 被引量:1
  • 3Neubauer DN. New and emerging phammcotherapeutic approaches for insomnia[ J]. lnt Rev Psychiatry, 2014,26:214 -224. 被引量:1
  • 4FDA. Suvorexant[EB/OL]. http://www, accessdata, fda. gov/ drugsatfda_does/label/2014/204569s0001bledt, pdf,2014 -08 - 13. 被引量:1
  • 5Yang LP. Suvorexant : first global approval [J].Drugs,2014,74 : 1817 - 1822. 被引量:1
  • 6PaIasz A, Lapray D, Peyron C, et al. Dual orexin receptor antago- nists - promising agents in the treatment of sleep disorders[ J]. lnt J Neuropsyehopharmacol, 2014,17 : 157 - 168. 被引量:1
  • 7Winrow CJ, Renger JJ. Discovery and development of orexin recep- tor antagonists as therapeutics for insomnia [ J ] ~ Br J Pharmacol, 2014,171:283 - 293. 被引量:1
  • 8Hoyer D, Jaeobson LH. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand? [ J]. Neurapeptides, 2013 ,47:477 - 488. 被引量:1
  • 9Mediavilla C, Risco S. Orexin: clinical and therapeutic impliea- tions[J].Rev Neurol, 2014,58:117 - 124. 被引量:1
  • 10Citrome L. Suvorexant for insomnia : a systematic review of the effi- cacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? [ J]. lnt J Clin Pract,2014,68:1429 - 1441. 被引量:1

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部